KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Receivables - Net (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of Receivables - Net data on record, last reported at $2.1 billion in Q4 2025.

  • For Q4 2025, Receivables - Net rose 27.55% year-over-year to $2.1 billion; the TTM value through Dec 2025 reached $2.1 billion, up 27.55%, while the annual FY2025 figure was $2.1 billion, 27.55% up from the prior year.
  • Receivables - Net reached $2.1 billion in Q4 2025 per VRTX's latest filing, up from $1.9 billion in the prior quarter.
  • Across five years, Receivables - Net topped out at $2.1 billion in Q4 2025 and bottomed at $929.1 million in Q2 2021.
  • Average Receivables - Net over 5 years is $1.5 billion, with a median of $1.6 billion recorded in 2023.
  • Peak YoY movement for Receivables - Net: skyrocketed 43.45% in 2022, then increased 0.66% in 2025.
  • A 5-year view of Receivables - Net shows it stood at $1.1 billion in 2021, then rose by 26.86% to $1.4 billion in 2022, then grew by 8.4% to $1.6 billion in 2023, then rose by 2.94% to $1.6 billion in 2024, then increased by 27.55% to $2.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Net were $2.1 billion in Q4 2025, $1.9 billion in Q3 2025, and $1.9 billion in Q2 2025.